This book reviews some aspects of dopamine mechanisms, both within and outside the
central nervous system, the pharmacology of bromocriptine and some features of …

Bromocriptine is an ergopeptine derivative and dopamine agonist that predominantly
stimulates the striatal D2 non-adenyl cyclase-linked dopamine receptors. Bromocriptine …

Objective: To evaluate the efficacy and safety of bromocriptine QR in type 2 diabetes.
Materials and Methods: 105 patients according to inclusion and exclusion criteria were …

D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on
animal and human studies, timed bromocriptine administration within 2 h of awakening is …

Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor
and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and …

Objective It is well known that bromocriptine has a suppressive effect on the prolactin
release in hyperprolactinemic patients. But it also has some adverse effects. The new, long …

Objective To review available data on the efficacy and safety of bromocriptine-QR (BQR)
and to consider its role in the management of Type 2 diabetes mellitus (T2DM). Methods …

The pharmacokinetics and endocrine actions of a long-acting form of bromocriptine
(Parlodel) were examined in a controlled study in 10 healthy volunteers receiving a single …

Bromocriptine alters the motor behaviour of animals and improves the motor defect of
parkinsonism. Changes in movement are accompanied by biochemical changes in the …

The animal pharmacology of bromocriptine has been thoroughly reviewed and will be briefly
summarized here.'Animal studies demonstrate a direct action on pituitary lact~ trophs …